Based on the IMROZ and BENEFIT data, would you recommend quadruplet therapy for non transplant eligible newly diagnosed multiple myeloma?
Community PollStarted
For what proportion of your transplant-ineligible patients with multiple myeloma will you plan to prescribe a quadruplet?
15 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center
Answered on
Excellent question - to add citations for those who missed ASCO 2024 (I did since I was on inpatient!) and would like to jump to the manuscripts:
- IMROZ: Isa-VRd versus VRd (Facon et al., PMID 38832972)
- BENEFIT/IFM 2020-05: Isa-VRd versus Isa-Rd (Leleu et al., PMID 38830994)
Both trials enrolled pati...
Join for free or sign in to see the full answer